RNTX
Rein Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$44.02M
P/E Ratio
—
EPS
$-1.95
Beta
1.40
52W High
$2.40
52W Low
$1.02
50-Day MA
$1.25
200-Day MA
$1.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rein Therapeutics Inc
Rein Therapeutics Inc (RNTX) is an innovative biopharmaceutical company committed to advancing next-generation therapies aimed at neurodegenerative disorders. Leveraging its proprietary technology platform that integrates advanced neuroscience with drug development, the company is poised to address critical unmet medical needs through a robust and diversified pipeline. Supported by a team of seasoned industry experts, Rein Therapeutics is strategically located in a rapidly evolving therapeutic landscape, presenting a compelling opportunity for institutional investors seeking to engage with pioneering healthcare innovations.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-21.93M |
| Operating Margin | 0.00% |
| Return on Equity | -139.90% |
| Return on Assets | -31.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.02 |
| Price-to-Book | 28.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.04M |
| Float | $21.45M |
| % Insiders | 0.07% |
| % Institutions | 38.60% |
Analyst Ratings
Consensus ($10.00 target)
1
Buy1
HoldData last updated: 4/9/2026